These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 36131190)

  • 21. Versatility of hydrogel-forming microneedles in in vitro transdermal delivery of tuberculosis drugs.
    Anjani QK; Permana AD; Cárcamo-Martínez Á; Domínguez-Robles J; Tekko IA; Larrañeta E; Vora LK; Ramadon D; Donnelly RF
    Eur J Pharm Biopharm; 2021 Jan; 158():294-312. PubMed ID: 33309844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spray-dried particles as pulmonary delivery system of anti-tubercular drugs: design, optimization, in vitro and in vivo evaluation.
    Garg T; Goyal AK; Rath G; Murthy RS
    Pharm Dev Technol; 2016 Dec; 21(8):951-960. PubMed ID: 26334961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.
    Steingart KR; Schiller I; Horne DJ; Pai M; Boehme CC; Dendukuri N
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD009593. PubMed ID: 24448973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and Evaluation of Chitosan Microparticles Based Dry Powder Inhalation Formulations of Rifampicin and Rifabutin.
    Pai RV; Jain RR; Bannalikar AS; Menon MD
    J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):179-95. PubMed ID: 26406162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.
    Steingart KR; Sohn H; Schiller I; Kloda LA; Boehme CC; Pai M; Dendukuri N
    Cochrane Database Syst Rev; 2013 Jan; (1):CD009593. PubMed ID: 23440842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Xpert
    Kohli M; Schiller I; Dendukuri N; Dheda K; Denkinger CM; Schumacher SG; Steingart KR
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012768. PubMed ID: 30148542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolution of rifampicin treatment for tuberculosis.
    Grobbelaar M; Louw GE; Sampson SL; van Helden PD; Donald PR; Warren RM
    Infect Genet Evol; 2019 Oct; 74():103937. PubMed ID: 31247337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dry powder inhalers of antitubercular drugs.
    Nainwal N; Sharma Y; Jakhmola V
    Tuberculosis (Edinb); 2022 Jul; 135():102228. PubMed ID: 35779497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria.
    Liu Y; Pertinez H; Ortega-Muro F; Alameda-Martin L; Harrison T; Davies G; Coates A; Hu Y
    J Antimicrob Chemother; 2018 Mar; 73(3):724-731. PubMed ID: 29244108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
    Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanopolymersomes as potential carriers for rifampicin pulmonary delivery.
    Moretton MA; Cagel M; Bernabeu E; Gonzalez L; Chiappetta DA
    Colloids Surf B Biointerfaces; 2015 Dec; 136():1017-25. PubMed ID: 26590894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rifampicin-Carbohydrate Spray-Dried Nanocomposite: A Futuristic Multiparticulate Platform For Pulmonary Delivery.
    Mehanna MM; Mohyeldin SM; Elgindy NA
    Int J Nanomedicine; 2019; 14():9089-9112. PubMed ID: 31819421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP).
    Ekqvist D; Bornefall A; Augustinsson D; Sönnerbrandt M; Nordvall MJ; Fredrikson M; Carlsson B; Sandstedt M; Simonsson USH; Alffenaar JC; Paues J; Niward K
    BMJ Open; 2022 Mar; 12(3):e054788. PubMed ID: 35273049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients.
    Heinrich N; Dawson R; du Bois J; Narunsky K; Horwith G; Phipps AJ; Nacy CA; Aarnoutse RE; Boeree MJ; Gillespie SH; Venter A; Henne S; Rachow A; Phillips PP; Hoelscher M; Diacon AH; ;
    J Antimicrob Chemother; 2015 May; 70(5):1558-66. PubMed ID: 25630641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.
    Mugusi S; Ngaimisi E; Janabi M; Mugusi F; Minzi O; Aris E; Bakari M; Bertilsson L; Burhenne J; Sandstrom E; Aklillu E
    Eur J Clin Pharmacol; 2018 Nov; 74(11):1405-1415. PubMed ID: 30003275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?
    van Ingen J; Aarnoutse RE; Donald PR; Diacon AH; Dawson R; Plemper van Balen G; Gillespie SH; Boeree MJ
    Clin Infect Dis; 2011 May; 52(9):e194-9. PubMed ID: 21467012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristics of infants exposed to maternal tuberculosis and chemoprophylaxis using 3 months of isoniazid and rifampicin.
    Mathivha KT; Velaphi S
    Paediatr Int Child Health; 2017 May; 37(2):129-134. PubMed ID: 27455907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.